Holly Longstreet, DO
Family Medicine · Hobart, INNPI 1588925655
Payments from drug & device makers
Across 152 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$403
- Novo Nordisk$335
- AbbVie$227
- AstraZeneca$215
- GSK$171
- Merck$169
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,719100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 25 | $403 |
| Novo Nordisk | 18 | $335 |
| AbbVie(2 entities) | 12 | $227 |
| AstraZeneca | 11 | $215 |
| GSK | 10 | $171 |
| Merck | 10 | $169 |
| Pfizer | 10 | $166 |
| Johnson & Johnson | 5 | $97 |
| Xeris Pharmaceuticals, Inc. | 5 | $96 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $87 |
| Amgen | 4 | $75 |
| Exact Sciences | 4 | $72 |
| Kowa Pharmaceuticals America, Inc. | 4 | $65 |
| Abbott | 3 | $61 |
| E.r. Squibb & Sons, L.L.C. | 4 | $57 |
| Dexcom, Inc. | 3 | $57 |
| Boehringer Ingelheim | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Sanofi Pasteur Inc. | 2 | $39 |
| Novartis | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Edwards Lifesciences | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Bayer | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$2,719 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $77,153 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $49,123 |
| JardianceEmpagliflozin | 25 | $35,650 |
| MounjaroTirzepatide | 27 | $33,861 |
| FarxigaDapagliflozin Propanediol | 28 | $32,635 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $20,638 |
| EliquisApixaban | 27 | $19,722 |
| JanuviaSitagliptin Phosphate | 20 | $18,109 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $6,540 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $5,662 |
| Memantine Hcl ErMemantine Hcl | 13 | $3,913 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $3,691 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 129 | $3,398 |
| SynthroidLevothyroxine Sodium | 32 | $2,329 |
| Gabapentin | 150 | $2,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $335 | $77,15346 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $171 | $73,452121 claims |
| Boehringer IngelheimJardiance | $47 | $35,65025 claims |
| Lilly USA, LLCMounjaro | $403 | $33,86127 claims |
| AstraZenecaFarxiga | $215 | $32,63528 claims |
| PfizerEliquis | $166 | $19,72227 claims |
| MerckJanuvia | $169 | $18,10920 claims |
| AbbVieSynthroid | $227 | $2,32932 claims |
| Almatica Pharma LLCSertraline Hcl | $16 | $56958 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Hobart
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.